Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before ...
newswise

Embolx Secures New CMS HCPCS Level II G-Code for Pressure-Generating Catheter Procedures Performed in the Physician Office (OBL)

SUNNYVALE, Calif., July 13, 2026 -- Embolx, Inc., a leader in advanced microcatheter technology for targeted embolization procedures, today announced that the Centers for Medicare & Medicaid Services ...
Becker's ASC

Drug Code Changes Included in July HCPCS Level II Updates

The July 1 quarterly HCPCS Level II update includes several drug/biological code changes, according to an AAPC release. Effective July 1, the HCPCS Level II code J7184 will be replaced with Q2041 ...
MarketScreener

Outlook Therapeutics, Inc. Submits HCPCS Level II Application To CMS For Permanent J-Code For LYTENAVA

Outlook Therapeutics, Inc. announced that it has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific Healthcare Common Procedure ...
MarketScreener

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA

ISELIN - Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for the treatment of ...